Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation

Melinda A. Biernacki,1,2 Yu-tzu Tai,3,4 Guang Lan Zhang,2 Anselmo Alonso,2 Wandi Zhang,2 Rao Prabhala,3,4 Li Zhang,2,3 Nikhil Munshi,3,5 Donna Neuberg,6 Robert J. Soiffer,3,4 Jerome Ritz,2,4 Edwin P. Alyea,3,4 Vladimir Brusic,2 Kenneth C. Anderson,3,4 and Catherine J. Wu2,4

1University of Connecticut School of Medicine, Farmington, CT; 2Cancer Vaccine Center and 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Medicine, Harvard Medical School, Boston, MA; 5Veterans Administration Boston Healthcare System, West Roxbury, MA; and 6Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

Targets of curative donor-derived graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT) remain poorly defined, partly because immunity against minor histocompatibility Ags (mHAgs) complicates the elucidation of multiple myeloma (MM)–specific targets. We hypothesized that syngeneic HSCT would facilitate the identification of GVM-associated Ags because donor immune responses in this setting should exclusively target unique tumor Ags in the absence of donor-host genetic disparities. Therefore, in the present study, we investigated the development of tumor immunity in an HLA-A0201+ MM patient who achieved durable remission after myeloablative syngeneic HSCT. Using high-density protein microarrays to screen post-HSCT plasma, we identified 6 Ags that elicited high-titer (1:5000–1:10 000) Abs that correlated with clinical tumor regression. Two Ags (DAPK2 and PIM1) had enriched expression in primary MM tissues. Both elicited Ab responses in other MM patients after chemotherapy or HSCT (11 and 6 of 32 patients for DAPK2 and PIM1, respectively). The index patient also developed specific CD8+ T-cell responses to HLA-A2–restricted peptides derived from DAPK2 and PIM1. Peptide-specific T cells recognized HLA-A2+ MM-derived cell lines and primary MM tumor cells. Coordinated T- and B-cell immunity develops against MM-associated Ags after syngeneic HSCT. DAPK1 and PIM1 are promising target Ags for MM-directed immunotherapy. (Blood. 2012;119(13):3142-3150)

Introduction

Clinical studies over the last 2 decades have highlighted the critical contribution of donor-derived immunity against tumors to the long-term curative effects of allogeneic hematopoietic stem cell transplantation (HSCT).1 The potency of this donor-derived graft-versus-tumor (GVT) response is clearly illustrated by the clinical success of therapies such as donor lymphocyte infusion2,3 and reduced intensity HSCT,4,5 which minimize or avoid chemotherapeutic and radiotherapy and rely instead on immunity to drive their antitumor effect.2-8 The beneficial GVT effects associated with these responses, however, are typically associated with detrimental GVHD responses.7,9 Preserving the benefits of GVT responses while minimizing toxicity from GVHD thus remains a critical unsolved issue in transplantation medicine.

Defining the target Ags of GVT and GVHD may provide insight into their mechanisms and suggest rational methods for their separation. Minor histocompatibility Ags (mHAgs) make up one major class of Ags against which potent donor-derived T- and B-cell immunity develops after HSCT. mHAgs with broad or nonhematopoietic cell expression are implicated in GVHD,10 whereas those with restricted hematopoietic expression play a well-accepted role in GVT responses.10-12 The extent to which nonpolymorphic tumor-associated Ags are targets is less well understood. Tumors may be distinguished from normal cells by genetic alterations, including chromosomal translocations. Tumors can also overexpress or aberrantly express genes compared with their normal counterparts.13 In support of the existence of immunogenic Ags with tumor-restricted expression, Nishida et al described T-cell immunity against leukemia cells after allogeneic HSCT that was not directed against mHAgs.14 The discovery of such naturally immunogenic tumor-associated Ags (TAAs) could lead to the development of immunotherapeutic strategies to target tumor in a selective fashion and thus avoid GVHD toxicity.

Because allogeneic HSCT can result in durable curative remission, it provides a useful clinical backdrop for identifying Ags that are naturally immunogenic to normal donor cells. However, defining TAAs in the allogeneic setting can be complicated by the presence of alloimmune responses. In the present study, we describe a context in which effective donor-derived tumor immunity occurred in the absence of alloimmunity: myeloablative syngeneic HSCT resulting in durable molecular remission in an individual with multiple myeloma (MM). Dissecting humoral immune responses by serologic screening after immune-mediated therapy15-18 or in premalignant conditions19 has been a successful strategy for identifying TAAs. We therefore examined the B-cell responses developing in this index patient. By screening plasma samples after HSCT against high-density protein microarrays, we identified 2 Ags, DAPK2 and PIM1, which elicited high-titer plasma Ab responses that were coordinated with Ag-specific CD8+ T-cell immunity. Consistent with the notion that these Ags are myeloma-specific targets, we found that peptides derived from...
these Ags further elicited T-cell responses against HLA-A2+ MM cell lines and primary MM plasma cells. Our results suggest a key role for TAAs that is distinct from mHAgS and that can elicit coordinated T- and B-cell responses to effect GVM immunity.

Methods

Patient samples and cell preparation

Heparinized blood and BM samples were obtained from patients and healthy donors enrolled in clinical research protocols at the Dana-Farber Harvard Cancer Center approved by the Human Subjects Protection Committee. BM mononuclear cells (BMMCs) or PBMCs were isolated by Ficoll/Hypaque density-gradient centrifugation, cryopreserved with 10% DMSO, and stored in vapor-phase liquid nitrogen until the time of analysis. Plasma was isolated by removal of the plasma layer after centrifugation of whole blood and cryopreserved at −80°C until the time of analysis.

Cell lines, plasmids, and peptides

The MM cell lines IM-9, RPMI 8226, MC/Car, and NCI-H929 were obtained from the American Type Culture Collection and lines OPM1 and OPM2 from Dr Ken Anderson (Dana-Farber Cancer Institute). DNA sequences encoding candidate Ags were acquired from the Dana-Farber Cancer Institute Center for Cancer Systems Biology Human ORFeome Collection (Dr Mark Vidal, Dana-Farber Cancer Institute), or from the PlasmID repository (Dr Joshua LaBaer, Harvard Institute of Proteomics) and cloned into the pDONR221 Gateway vector (Invitrogen). The inserts of all of the acquired plasmids were verified by sequencing and then shuttled into a Gateway-converted mammalian expression vector containing a T7 promoter and a C-terminus GST tag (Wagner Montor, Harvard Institute of Proteomics) using LR Clonase (Invitrogen). DAPK2 and PIM1 were PCR cloned into pCNA3 using the following primers: PIM1 forward, 5’-AAAGG AAGCTT ATGGGCTTTGAAAAATCT-3’, reverse, 5’-CCGG GAATTC CTATTTGCTGGGCAGGC-3’; and DAPK2 forward, 5’-AAAGG GGTACC ATGTTCAAGGCTCTACAT-3’, reverse, 5’-CCGG TTCGAG TTAGGGGATCC-GTCTGCTC-3’. Synthetic peptides encoding the influenza M1 58-66 epitope (FLuM1, GILGFVFTL) and predicted HLA-A2*—binding 9-mer peptides derived from DAPK2 and PIM1 were obtained from New England Peptide.

Serologic screening using high-density protein microarrays

Commercial protein microarrays (Human ProtoArray Version 4; Invitrogen) were probed with plasma samples as described previously. All samples were screened using arrays from the same printing lot. The microarrays contained approximately 8000 N-terminus GST-fusion human proteins expressed in an insect cell line and spotted on nitrocellulose-coated glass slides. The protein microarrays were processed at 4°C according to the manufacturer’s recommendations. In brief, after blocking, patient plasma (diluted 1:150) was applied to the microarray surface for 90 minutes, and Ab-Ag interactions were detected with Alexa Fluor 647-conjugated anti-human IgG (H and L chain) Ab (1:2000; Invitrogen). Lot-specific protein spot definitions provided by the microarray manufacturer were manually aligned to the image data. Fluorescence intensities were quantified using GenePix Pro Version 5.0 software (Molecular Devices) at 635 nm, 100% power, and 600 gain. Significant Ab-protein interactions were determined using Prospector Version 5.1.0 analysis software (Invitrogen) and an algorithm20 that incorporates the contribution of protein spot concentration to signal intensity. Signal change between pre-treatment or control plasma and post-treatment plasma was considered significant if the change in both (1) the signal magnitude (Z_{delta}), defined as Z_{post} − max(0, Z_{pre}) and (2) the ratio (Z_{pre}), defined as Z_{post}/max(1,Z_{pre}), were greater than a cutoff value n (n = 5 for significant Ags, called “candidate Ags”). All candidate Ags selected for the final analysis had significantly higher reactivity at the maximum post-HSCT time point compared with 2 normal controls, the patient’s donor, and a prechemotherapy patient sample.

Validation and survey of Ag-specific Ab responses to candidate Ags

We first validated the results of serologic screening using an immunoprecipitation-based method. In brief, candidate Ags in the pCITE mammalian expression vector were transcribed and translated in vitro with rabbit reticulocyte lysate (TNT T7 Quick Coupled Transcription/Translation; Promega) using biotinylated lysine transfer RNA (Transcend iRNA; Promega). Expressed protein was immunoprecipitated using patient plasma, as described previously. Immunoprecipitated proteins were subjected to SDS-PAGE on 10% Tris-HCl polyacrylamide gels (Bio-Rad), transferred to nitrocellulose membranes in Tris-glycine buffer with 20% methanol (blocked overnight in 1× TBS/0.5% Tween-20), and detected using streptavidin-HRP conjugate (1:20 000 dilution; MP Biomedicals).

We further developed ELISA assays in which recombinant DAPK2 and PIM1 proteins, expressed in a baculovirus-infected insect cell line (Ultimate ORF Collection; Invitrogen) were applied at 5 μg/mL to Nunc C96 Maxisorp plates (Fisher Scientific) in carbonate buffer (pH 9.6) overnight at 4°C, then blocked in PBS with 0.05% Tween plus 2% milk. Plasma samples were added to duplicate wells in blocking buffer (1:200 dilution) and incubated for 3 hours at 25°C. Binding of patient Ig to test proteins was detected using goat anti-human IgG-alkaline phosphatase secondary Ab (1:1000 dilution, Jackson ImmunoResearch Laboratories) and visualized with p-nitrophenyl phosphate substrate (Sigma-Aldrich). Absorbance was read at 405 nm. Samples were defined as Ag reactive if the signal was greater than 2 SDs above the mean of 10 normal volunteers.

Quantitative PCR for molecular detection of disease and for gene expression

The clonotypic IgH sequence of patient A was identified using a panel of VH-specific PCR primers, as described previously. Based on this sequence, a quantitative TaqMan PCR assay was designed such that a sequence-specific probe was located in the region of junctional diversity (Applied Biosystems). This assay was applied to reverse-transcribed RNA (SuperScript II reverse transcriptase; Invitrogen) isolated from PBMCs, BMMCs, or CD138−-selected (Millenyi Biotec) BMMCs (RNasey kit; Qiagen).

Direct quantification of gene expression of candidate Ags was performed using gene-specific TaqMan Gene Expression Assays (Applied Biosystems), applied to reverse-transcribed RNA (RNasey; Qiagen) from total PBMCs immunomagnetically selected CD19+ cells from healthy donors (Miltenyi Biotec) or from BMMCs of MM patients (>95% malignant plasma cells by immunohistochemistry). All PCR reactions consisted of: 50°C for 1 minute for 1 cycle, 95°C for 10 minutes for 1 cycle, and 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute (7500 Fast Real-time PCR cycler; Applied Biosystems). Test transcripts were quantified relative to GAPDH transcripts by calculating 2 × (GAPDH C_{T} − target C_{T}). The statistical significance between sample groups was determined by 1-sided exact Wilcoxon rank-sum test.

Generation of cell lysates and Western blotting

Whole-cell lysate was generated from tumor cell lines or from patient samples by lysis with RIPA buffer (1% NP40, 0.5% deoxycholate, 0.1% SDS, 150mM sodium chloride, 50mM HEPES, pH 7.4) in the presence of protease inhibitors. Lysates (20 μg of total protein per lane) were subjected to 4%–15% gradient SDS-PAGE in Tris-glycine buffer, and transferred onto nitrocellulose membranes in Tris-glycine buffer containing 20% methanol. Rabbit polyclonal DAPK2 Ab (1:1000; ProSci) and mouse PIM1 mAb (clone 12H8, 1:1000; Santa Cruz Biotechnology) were used for Western blotting. Ab to β-actin (1:3000; Sigma-Aldrich) was used as a control to ensure equal loading of lanes.

Generation of APCs

To generate dendritic cells, CD14+ cells were isolated from leukapheresis material by immunomagnetic enrichment (Miltenyi Biotec), and cultured in the presence of 50 ng/mL of GM-CSF (Genzyme) and 20 ng/mL of IL-4 (R&D Systems) in medium composed of IMDM (Invitrogen) supplemented
with 10% human AB serum (Cellgro), 2 mM glutamine (Cellgro), 50 μg/mL of human transferrin (Roche), 5 μg/mL of human insulin (Sigma-Aldrich), and 15 μg/mL of gentamicin (Invitrogen). On days 3 and 6, 50% fresh medium with cytokines was added. On day 7, cells were matured for 48 hours with prostaglandin E2 (1 μg/mL; Sigma-Aldrich), IL-1α (10 ng/mL; BD Biosciences), IL-6 (1000 U/mL; BD Biosciences), and TNFα (10 ng/mL; Genzyme). The TAP-deficient, HLA-A*0201–expressing cell line T2 was obtained from Dr Peter Cresswell (Yale University School of Medicine, New Haven, CT). PIM1 and DAPK2 were expressed in APCs by nucleofecting 20 μg of DNA plasmids encoding these genes into 2 × 105 cells K562 cells, stably expressing HLA-A*0201 in 100 μL of PBS/10% HEPES buffer (Amaxa Nucleofector, Program T-016; Lonza). For some experiments, HLA class I–blocking Ab was used (clone w6/32).

### T2-binding assay

The prediction servers IEDB ANN, NetMHC ANN, and MHC-I Multiple Matrix were used to predict HLA-A*0201–binding nonamer peptides derived from DAPK2 and PIM1. Synthesized peptides were tested for their HLA-A2–binding ability using the T2-binding assay.23 In brief, 1 million T2 cells per condition were washed extensively with serum-free IMDM (Invitrogen) and then incubated in serum-free IMDM with or without individual predicted peptides or the influenza M1 peptide at 40 μM. Cells were harvested at 0 and 24 hours, stained with FITC-labeled mouse anti–HLA-A*0201 (clone BB7.2; BD Pharmingen), and fixed in 2% formalin overnight. Fixed cells were analyzed by flow cytometry (FACSCanto II; BD Biosciences) to obtain the mean fluorescence intensity (MFI) of 10,000 events. Fluorescence index was calculated as follows: (MFI with peptide – MFI without peptide)/MFI without peptide).

#### Detection of DAPK2 and PIM1-specific T-cell responses

Patient reactivity to peptides was tested by ex vivo stimulation using total PBMCs isolated from fresh patient blood collected after HSCT. One to 2 million PBMCs were stimulated with 10 μM concentrations of individual peptides in the presence of 10 ng/mL of IL-7 for 7 days, and then tested by ELISpot assay. These peptides included the DAPK2-derived peptide D1_36-166 (MLLDKNIPI) and the PIM1-derived peptide P4_191-199 (ALLKD-TVYVT). For some experiments, banked PBMCs were thawed and stimulated with irradiated T2 cells, pulsed with 10 μg/mL of D1 or P4 peptide in RPMI 1640 (Invitrogen) supplemented with 10% human AB serum (Cellgro), 2 mM glutamine (Cellgro), 10 mM HEPES (Cellgro), and 15 μg/mL of gentamicin (Invitrogen) in the presence of 10 ng/mL of IL-7 (Endogen). ELISpot was performed using autologous matured dendritic cells pulsed with 10 μM peptide (20,000 cells/well) co-incubated with the stimulated PBMCs (20,000 cells/well) plated in duplicate on Multi-Screen-IP plates (Millipore) for 24 hours. IFN-γ secretion was detected using capture and detection Abs as directed by the manufacturer (Mabtech) and imaged using an Immunospot Series Analyzer (Cellular Technology). Ag-specific reactivity was also detected by staining of cells with PE-conjugated peptide-specific tetramer (provided by the National Institutes of Health Tetrramer Core Facility, Emory University), together with anti–CD8–FITC (Beckmann Coulter) and analyzed by flow cytometry (FACS Aria II, BD Biosciences).

### Generation and testing of D1- and P4-specific T-cell lines

Patient PBMCs were thawed and stimulated weekly for 28 days with irradiated T2 cells (5000 rad) pulsed with 10 μg/mL of peptides D1 or P4.

#### Results

### Complete molecular remission of MM after syngeneic HSCT for patient A

We identified a patient (patient A) who achieved complete molecular remission after syngeneic HSCT. As summarized in Table 1, this patient was a 48-year-old HLA-A2+ woman with progressive stage II IgG MM diagnosed 9 years before HSCT. Before HSCT, she underwent induction with dexamethasone, lenalidomide, and bortezomib. At the time of HSCT, she demonstrated persistent residual disease with a serum monoclonal protein level of 0.6 g/dL and detectable monoclonal gammopathy on immunofixation (Figure 1A). After myeloablative conditioning with high-dose melphalan, the patient received CD34+ peripheral blood stem cells (6.85 × 106 cells/kg) from her genotypically identical twin. At approximately 2.6 months after HSCT, neither serum monoclonal protein nor detectable monoclonal gammopathy were detectable. Tumor-specific IgH transcripts remained detectable by quantitative real-time PCR of CD138+ BM RNA, albeit with an almost 4-log reduction from pre-HSCT levels. However, as shown in Figure 1B, repeat analysis of total BMMCs from 24 to >60 months after HSCT demonstrated continuing molecular remission. Having observed the effective elimination of MM in this patient, we sought to identify the tumor-associated Ags targeted by her syngeneic donor graft.

#### Serologic screening identifies 6 candidate Ags, including DAPK2 and PIM1

We screened plasma samples from our index patient at 9 serial time points before and after HSCT against commercially available protein microarrays consisting of recombinant proteins expressed from approximately 8000 open reading frames in baculovirus-infected insect cell lines and spotted on glass slides. Binding of plasma Ab to spotted proteins was detected with fluorescently labeled anti–human IgG (Figure 2A). Negative controls included plasma from the patient’s identical twin donor and from 2 age-, sex-, and parity-matched healthy controls. All 9 samples were

---

### Table 1. Clinical characteristics of patient A

<table>
<thead>
<tr>
<th>Age/sex</th>
<th>Time from diagnosis to HSCT, mo</th>
<th>Therapies prior to HSCT</th>
<th>HSCT conditioning regimen</th>
<th>Stem cell dose, cells/kg body wt</th>
<th>Stem cell source</th>
<th>Time from HSCT to complete response, mo&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Time from HSCT to molecular response, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>48/F</td>
<td>108</td>
<td>Lenalidomide, bortezomib, dexamethasone</td>
<td>High-dose melphalan</td>
<td>6.85 × 10&lt;sup&gt;6&lt;/sup&gt;</td>
<td>PBSCs</td>
<td>2.6</td>
<td>24</td>
</tr>
</tbody>
</table>

<sup>a</sup>Defined as negative immunofixation and monoclonal protein of 0 g/dL. PBSCs indicates peripheral blood stem cells.
screened in 2 replicates against 1 lot of protein microarrays. Significance of Ab binding to protein spots was determined using established analytical methods.20 Candidate Ags were defined as those proteins eliciting significantly more plasma Ab binding from post-HSCT plasma compared with pre-HSCT plasma.

Six proteins (C1orf116, DAPK2, PDGFRB, PIM1, PRKCB1, and RELA) met the criteria for candidate Ags (Table 2). None elicited significant Ab reactivity from any of the 4 negative control plasma samples based on calculated \( Z \)-scores. The increase in significance (\( Z \)-score) of Ab binding for post-HSCT plasma was 17- to 10 615-fold higher than pre-HSCT \( Z \)-scores (Figure 2B). These significant Ag-specific Ab responses arose in 2 general patterns, early (peaking at 3 months: DAPK2, PIM1, and PRKCB1) or late (peaking at or after 12 months: C1orf116, PDGFRB, and RELA). We validated these statistical findings by confirming the detection of early- and late-peaking patterns of Ag-specific B-cell reactivity by measuring the amount of independently produced Ag immunoprecipitated by post-HSCT plasma–derived Ig from patient A (representative examples are shown in Figure 2C). To more accurately quantify the immune responses against candidate Ags, we performed ELISA assays in which recombinant protein expressed in baculovirus-infected insect cell lines was used as a coating Ag. Using ELISA, the Ab responses against DAPK2

Table 2. Candidate Ags identified by protein microarray screening

<table>
<thead>
<tr>
<th>Gene</th>
<th>symbol*</th>
<th>NCBI gene ID</th>
<th>Chromosome</th>
<th>Size, aa</th>
<th>Maximum post-HSCT significance†</th>
<th>Maximum time point, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAPK2</td>
<td>79098</td>
<td>1q32.1</td>
<td>370</td>
<td>++</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>PIM1</td>
<td>23604</td>
<td>15q22.31</td>
<td>313</td>
<td>++</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>PRKCB1</td>
<td>5159</td>
<td>5p31-q32</td>
<td>671</td>
<td>++</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>C1orf116</td>
<td>5292</td>
<td>6p21.2</td>
<td>601</td>
<td>++</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>PDGFRB</td>
<td>5579</td>
<td>16p11.2</td>
<td>1106</td>
<td>++</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>RELA</td>
<td>5970</td>
<td>11q13</td>
<td>551</td>
<td>+</td>
<td>15</td>
<td>15</td>
</tr>
</tbody>
</table>

*UniProt identifiers: DAPK2, Q1RMF4; PIM1 isoform 2, P11309–2; PRKCB1, P05771; C1orf116 (SARG), Q9BW04; PDGFRB, P09619; and RELA, Q04206.
† + indicates 10- to 20-fold increase in significance (\( Z \)-score) of Ab binding in posttransplantation plasma; ++, 20- to 50-fold increase; and ++++, > 50-fold increase.

Figure 2. Serologic screening identifies high-titer Ab responses against DAPK2, PDGFRB, PIM1, and PRKCB1 developing after syngeneic HSCT. (A) Plasma samples collected from patient A at serial time points before and after HSCT were screened by ProtoArray protein microarray. Subarrays demonstrating DAPK2 reactivity are highlighted in the gray boxes. Spots seen in the bottom right corner of all subarray images are control spots. (B) Arrays were analyzed using 2 methods described previously.48 Six Ags, DAPK2, PDGFRB, C1orf116, RELA, PIM1, and PRKCB1, elicited significantly greater reactivity after HSCT compared with before HSCT. Significance (\( Z \)-scores) scores of Ab reactivity at time points are shown. (C) Ag binding was confirmed by immunoprecipitation of biotinylated target Ags expressed in vitro in rabbit reticulocyte lysate by patient plasma at serial time points. Immunoprecipitated Ags were detected using streptavidin-conjugated secondary Ab. Representative Western blots are shown. The first lane is whole rabbit reticulocyte lysate expressing target Ags that was not subjected to immunoprecipitation. (D) Plasma samples (1:200 dilution) collected from patient A at serial time points before and after HSCT were tested by ELISA (plates coated with 5 \( \mu \)g/mL of recombinant protein). Ab IgG responses against DAPK2 and PIM1 arose and peaked at 3 months after HSCT. (E) Candidate Ags eliciting high-titer Ab responses, as indicated by titration studies of serum using ELISA assays. Reactivity remained detectable at dilutions of 1:10 000 (DAPK2) and 1:5000 (PIM1).
and PIM1 by patient A closely mirrored the reactivity pattern calculated based on significance score, peaking at 3 months after HSCT (Figure 2D), whereas only low or minimal reactivity was detected in pre-HSCT samples. Titration by serial dilution of plasma with maximal reactivity against Ags confirmed the high-titer reactivity against both DAPK2 and PIM1 (1:10,000 and 1:5000, respectively; Figure 2E).

**DAPK1 and PIM1 are expressed in primary myeloma cells**

Tumor-associated Ags are commonly overexpressed in tumor tissue. Using quantitative real-time PCR, DAPK2 and PIM1 were enriched in transcript expression in BM from a primary MM patient containing $>95\%$ malignant plasma cells (Figure 3A). Mean relative transcript levels of DAPK2 (normalized to GAPDH) in 5 primary MM samples were 4.8-fold higher than in 4 healthy donor PBMCs ($P = .008$), and comparable transcript levels were observed between primary MM and 5 healthy donor B-cell samples. Mean relative transcript levels of PIM1 in 5 primary MM samples were 2.1- and 2-fold higher than in 4 healthy donor B cells ($P = .07$) and PBMCs ($P = .056$), respectively. The RNA expression levels of the 4 other candidate Ags were similar between healthy and malignant hematopoietic tissues.

Western blot analysis of PIM1 and DAPK2 expression (representative examples are shown in Figure 3B) showed that DAPK2 was expressed in 10 of 13 primary MM samples tested, and that PIM1 was expressed in 9 of 13 primary MM samples. DAPK2 was also expressed in healthy donor CD19$^+$ B cells and BMMCs, whereas PIM1 was highly expressed in 1 of 2 healthy donor BMMC samples. Furthermore, PIM1 and DAPK2 were expressed in all 7 MM cell lines (IM9, MC/Car, MM1S, NCI-H929, OPM1, RPMI 8226, and U266) tested by Western blot analysis (Figure 3C).

**Ab responses against DAPK2 and PIM1 are associated with effectively treated MM**

To determine whether candidate Ags are commonly immunogenic in other patients with effective antitumor immunity, we used ELISA to test serial plasma samples from 6 MM patients with effective GVM responses after allogeneic HSCT. All 6 patients had achieved complete remissions of 2 years or more without clinically evident GVHD. Significant Ab responses to DAPK2 and PIM1 was defined as reactivity greater than 2 SDs above the mean reactivity of 10 normal donors, and was observed in 3 of 6 patients. Two of these 3 patients developed 2-fold or greater increases in Ab reactivity against DAPK2 after autologeneic HSCT, whereas 2 of 3 developed similar increases in reactivity against PIM1 (Figure 4A). Patient 2 showed gradually increasing levels of DAPK2 reactivity from pre-HSCT levels that peaked at 12 months after HSCT (5-fold increase over before HSCT). Patient 3 developed a 2-fold and 4-fold increase in DAPK2 and PIM1 reactivity at 6 months post-HSCT, respectively, that subsequently diminished. Only an early posttransplantation sample was available for patient 5; however, this patient had a striking increase (78-fold) in post-HSCT reactivity against PIM1 compared with pre-HSCT levels.

To further explore the relationship between MM and Ab responses against DAPK2 and PIM1, we performed additional ELISA studies on MM patients before any therapy ("untreated," $n = 10$), after standard chemotherapy ($n = 16$), and after autologous HSCT ($n = 10$), in healthy volunteers ($n = 10$). As summarized in Figure 4B, 6 of 16 MM patients treated with standard chemotherapy (37.5%) and 3 of 10 MM patients treated with autologous HSCT (30%) displayed Ab reactivity against DAPK2. In contrast, reactivity against DAPK2 was seen in only 1 of 10 untreated MM patients (10%) and in 0 of 10 normal volunteers (0%). For PIM1, 3 of 16 chemotherapy-treated patients (18.8%) and 1 of 10 patients receiving autologous HSCT (10%) were reactive against the Ag. One of 10 untreated MM patients (10%) and 1 of 10 normal volunteers (10%) had Ab responses to PIM1. Our results demonstrate that humoral immunity against DAPK2 and PIM1 commonly occurs in the setting of treatment for MM.

**DAPK2 and PIM1 peptides elicit T-cell reactivity in patient A**

To determine whether the high-titer B-cell responses to PIM1 and DAPK2 were coordinated with cell-mediated Ag-specific immunity, we tested posttransplantation T cells of patient A for their ability to recognize selected DAPK2- and PIM1-derived 9-mers. Because the patient was HLA-A2 positive, we focused our inquiry on DAPK2- and PIM1-derived peptides that were
predicted to bind to this HLA allele. We used consensus predictions of the servers IEDB-ANN, NetMHC-ANN, and MHC-I Multiple Matrix to identify a total of 10 DAPK2-derived (D1-D10) and 7 PIM1-derived (P1-P7) nonameric peptides. All 17 peptides were confirmed to bind to HLA-A2 by the T2-binding assay (Table 3). We therefore tested all 17 peptides against fresh patient PBMCs obtained at 2.5 years after HSCT using an ex vivo stimulation assay.

After 7 days of expansion to predicted peptides, T-cell reactivity to the peptides was assessed using IFN-γ secretion (ELISpot assay). As shown in Figure 5A, we observed a 3.8-fold increase in IFN-γ secretion in response to stimulation with D1 peptide (8 spot-forming counts [SFCs] per 20,000 cells or 0.038%) compared with the mean SFCs for the other DAPK2-derived peptides (range, 0.6-1.6 SFCs per 20,000 cells [0.003%-0.008%]). Similarly, we observed a striking T-cell response to the PIM1-derived peptide P4 (22 SFCs per 20,000 cells or 0.11%; Figure 5B). Lower levels of reactivity against P1, P2, P5, and P7 were also observed, with frequencies of reactivity in PBMCs of 0.026%, 0.030%, 0.015%, and 0.018%, respectively. The frequency of reactivity for the remainder of the PIM1 peptides was less than 0.005%.

Because of the evidence of marked memory responses in patient A to peptides D1 and P4, subsequent experiments were focused on the characterization of T-cell responses against these 2 predicted peptides. D1- and P4-specific T cells were isolated by peptide-specific tetramers and expanded. These T-cell lines were enriched for D1-reactive (6.6%) and P4-reactive (12%) T cells (Figure 6A).

**Table 3. Predicted peptides derived from candidate Ags DAPK2 and PIM1**

<table>
<thead>
<tr>
<th>Protein</th>
<th>ID</th>
<th>Position</th>
<th>Sequence</th>
<th>Consensus rank*</th>
<th>T2 binding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DAPK2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D1</td>
<td>156</td>
<td>MLLKDKNIP</td>
<td>3</td>
<td>3.92</td>
<td>2.28</td>
</tr>
<tr>
<td>D2</td>
<td>316</td>
<td>KLFSIVSLS</td>
<td>6</td>
<td>0.69</td>
<td>0.06</td>
</tr>
<tr>
<td>D3</td>
<td>220</td>
<td>LLGAPSPFL</td>
<td>10</td>
<td>1.78</td>
<td>0.98</td>
</tr>
<tr>
<td>D4</td>
<td>129</td>
<td>HIQVLDG</td>
<td>13</td>
<td>0.13</td>
<td>0.02</td>
</tr>
<tr>
<td>D5</td>
<td>132</td>
<td>QILDGVNL</td>
<td>17</td>
<td>1.92</td>
<td>0.18</td>
</tr>
<tr>
<td>D6</td>
<td>205</td>
<td>GLEADMWSI</td>
<td>19</td>
<td>1.50</td>
<td>0.00</td>
</tr>
<tr>
<td>D7</td>
<td>186</td>
<td>NIFGTPFVEV</td>
<td>26</td>
<td>2.99</td>
<td>0.07</td>
</tr>
<tr>
<td>D8</td>
<td>81</td>
<td>VHHNVITL</td>
<td>26</td>
<td>2.05</td>
<td>0.36</td>
</tr>
<tr>
<td>D9</td>
<td>211</td>
<td>WSGTIVT</td>
<td>29</td>
<td>0.14</td>
<td>0.00</td>
</tr>
<tr>
<td>D10</td>
<td>212</td>
<td>SIGTIVT</td>
<td>35</td>
<td>0.23</td>
<td>0.00</td>
</tr>
<tr>
<td><strong>PIM1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>1</td>
<td>MLLSKINSLS</td>
<td>3</td>
<td>1.19</td>
<td>0.00</td>
</tr>
<tr>
<td>P2</td>
<td>183</td>
<td>KLDFGSSGA</td>
<td>7</td>
<td>0.17</td>
<td>0.00</td>
</tr>
<tr>
<td>P3</td>
<td>118</td>
<td>LILERPVP</td>
<td>14</td>
<td>1.56</td>
<td>2.68</td>
</tr>
<tr>
<td>P4</td>
<td>191</td>
<td>ALLKDTVTY</td>
<td>16</td>
<td>1.03</td>
<td>0.00</td>
</tr>
<tr>
<td>P5</td>
<td>147</td>
<td>FFVQDLEAV</td>
<td>16</td>
<td>0.57</td>
<td>0.04</td>
</tr>
<tr>
<td>P6</td>
<td>265</td>
<td>HLRWCLAL</td>
<td>21</td>
<td>0.85</td>
<td>0.14</td>
</tr>
<tr>
<td>P7</td>
<td>2</td>
<td>LLSKINSLA</td>
<td>21</td>
<td>1.8</td>
<td>0.39</td>
</tr>
</tbody>
</table>

*Consensus rank score represents the composite ranking of peptides predicted by all the 3 servers (IEDB-ANN, NetMHC-ANN, and MHC-I multiple matrix). The lower the composite rank number, the higher the predicted binding affinity. FI-0 indicates the fluorescence intensity at 0 hours; and FI-I4, fluorescence intensity at 24 hours.

**Figure 4. MM treatment is associated with the development of Ab responses against DAPK2 and PIM1.** (A) Plasma samples from 5 MM patients who demonstrated GVM responses (defined as clinical remission > 2 years) without GVHD were tested by ELISA. Three patients (Pt. 2, 3, and 5) had new or markedly increased Ab reactivity to DAPK2 and/or PIM1 after HSCT. The dashed line indicates a cutoff based on 2 SD above the mean of Ab reactivity of 10 normal donors for each Ag. (B) Ab responses against DAPK2 (black bars) and PIM1 (gray bars) are also seen by ELISA in MM patients treated with standard chemotherapy or autologous HSCT, but are minimal in patients with untreated MM or healthy donors.
results demonstrate that the D1 and P4 immunogenic epitopes are commonly presented on myeloma cells by HLA-A2 molecules.

Discussion

Syngeneic HSCT for patients with MM produces higher complete remission rates, decreased relapse rates, and improved survival compared with autologous HSCT.25-27 The clinical superiority of syngeneic over autologous HSCT has been attributed to the absence of tumor contamination28,29 in the donor graft, and has been hypothesized to also involve the ability to reconstitute normal donor immunity in a MM Ag-rich environment. The results of the present study demonstrate the development of bona fide GVM immunity in the syngeneic setting, providing evidence that immunologic factors contribute to improved outcomes after syngeneic HSCT. Our findings are supported by previous studies of MM patients successfully treated with donor lymphocyte infusion, an established therapy with well-characterized GVM activity3,4,7,8 in which potent B- and T-cell responses against TAAs developed in temporal association with effective MM elimination.15,30 In the present study, disease regression after syngeneic HSCT was likewise associated with potent coordinated B- and T-cell responses against 2 overexpressed MM-associated Ags (DAPK2 and PIM1).

Through this system, we identified DAPK2 and PIM1 as potentially promising targets for myeloma-specific immunotherapy, because Ag-specific T cells against both Ags were consistently reactive against HLA-A2+ primary tumor cells.

Both PIM1 and DAPK2 have been shown previously to play functional roles in lymphoid malignancies, including MM. PIM1 is a known proto-oncogene that participates in the c-myc–signaling pathway31 and has established associations with B-cell lymphomas and other malignancies.32 Epigenetic silencing of DAPK2, a proapoptotic serine/threonine protein kinase33 with a tumor-suppressor function, and of related death-associated protein kinases has been observed in multiple neoplasms,34 including MM.35 in
that proteins complexed with nucleic acid are immunostimulatory, providing a plausible mechanism of immunogenicity for the nuclear protein PIM1. Expression of DAPK2 generates apoptosis, and apoptotic blebs have been reported to possess enriched expression of immunogenic Ags.

Mounting evidence suggests that tumor Ags that elicit coordinated T- and B-cell immunity are viable targets for tumor-specific immunotherapy. The phenomenon of cross-presentation, in which immune complexes of Ig and exogenous Ag bind FcyR on dendritic cells and in which internalized Ag is presented on MHC class I molecules, provides a link between B-cell and CD8 T-cell responses. Both post-vaccination patient serum and mAbs have been shown to enhance cell-mediated tumor immunity, and these mechanisms are potentially relevant for DAPK2 and PIM1.

Our tool kit for generating effective vaccines has increased greatly in recent years, and includes the development of novel vaccine-delivery methods, more potent adjuvants, and highly active checkpoint blockade inhibitors. In this context, defining true tumor-specific Ags is of utmost importance to ensure that potent and focused immune responses leading to effective destruction of tumor cells can be implemented without eliciting autoimmunity. DAPK2 and PIM1, as targets of coordinated humoral and cellular immunity identified in the context of an effective GVM response, are promising targets for future MM-specific immunotherapy.

Acknowledgments
The authors thank Maris Handley, Suzan Lazo-Kallanian, and John Daley for their assistance with flow cytometry; Dr John Donovan for his vital help in designing the tumor-specific IgH-quantitative PCR assay; and the clinical transplantation team at the Dana-Farber Cancer Institute for their assistance with patient samples.

This work was supported by the Multiple Myeloma Research Foundation and the Pasquarrello Tissue Bank. C.J.W. also received a Miles and Eleanor Shore Award, a grant from the National Cancer Institute (5R21CA115043-2), the Early Career Scientist-Scientist Award of the Howard Hughes Medical Institute, and a clinical investigator award supported by the Damon-Runyon Cancer Research Foundation (CI-38-07).

Authorship

Contribution: M.A.B. and C.J.W. designed the study, performed the experiments, analyzed the data, and wrote the manuscript; A.A., W.Z., and L.Z. performed the experiments; G.L.Z., D.N., and V.B. analyzed the data; and Y.-T., R.P., N.M., R.J.S., J.R., E.P.A., and K.C.A. provided vital clinical samples.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Catherine J. Wu, MD, Dana-Farber Cancer Institute, Harvard Institutes of Medicine, Rm 416B, 77 Avenue Louis Pasteur, Boston MA 02115; e-mail: cwu@partners.org.

References


